Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial

Competing interests M.S.v.d.H. has received institutional funding from Bristol Myers Squibb to finance the INDIBLADE ...